Literature DB >> 12120225

The pathobiochemistry of hereditary pancreatitis: studies on recombinant human cationic trypsinogen.

M Sahin-Tóth1.   

Abstract

BACKGROUND/AIMS: This study attempts to identify the biochemical alterations in human cationic trypsinogen and trypsin caused by the hereditary pancreatitis-associated mutations Arg117-->His and Asn21-->Ile.
METHODS: Recombinant wild-type and mutant human cationic trypsinogens were expressed in Escherichia coli and purified to homogeneity, and trypsin autolysis and trypsinogen autoactivation were characterized.
RESULTS: Both mutations significantly enhanced the autoactivation of human cationic trypsinogen. In addition, the Arg117-->His mutation inhibited autocatalytic inactivation of trypsin, while the Asn21-->Ile mutation had no such effect.
CONCLUSIONS: The findings support the notion that enhanced trypsinogen activation in the pancreas is the common initiating step in hereditary pancreatitis, whereas trypsin stabilization plays a role in cases associated with the Arg117-->His mutation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12120225     DOI: 10.1159/000055848

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  4 in total

Review 1.  Recent insights into the cellular mechanisms of acute pancreatitis.

Authors:  Laura I Cosen-Binker; Herbert Y Gaisano
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

2.  Characterisation of a transgenic mouse expressing R122H human cationic trypsinogen.

Authors:  Lena Selig; Ulrich Sack; Sebastian Gaiser; Günter Klöppel; Vuk Savkovic; Joachim Mössner; Volker Keim; Hans Bödeker
Journal:  BMC Gastroenterol       Date:  2006-10-27       Impact factor: 3.067

3.  Risk management in patients with severe acute pancreatitis.

Authors:  Herwig Gerlach
Journal:  Crit Care       Date:  2004-11-08       Impact factor: 9.097

4.  Protein surface charge of trypsinogen changes its activation pattern.

Authors:  Karin Buettner; Thomas Kreisig; Norbert Sträter; Thole Zuchner
Journal:  BMC Biotechnol       Date:  2014-12-28       Impact factor: 2.563

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.